Targeting Aggressive Forms of Cancer: Sunshine Bio (OTCBB: SBFM) and Roche (OTCBB: RHHBY)

Northern, WI 7/9/12 (StreetBeat) -- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a report on biotech companies targeting aggressive forms of cancer; Roche’s (OTCBB: RHHBY) Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its lead compound, Adva-27a.

Roche is the largest biotech company in the world and Sunshine Biopharma is a small microcap biopharma company. The two genes associated with aggressive forms of cancer are Her2 and Top2; Roche is targeting Her2-Positive patients and Sunshine Biopharma is targeting multidrug resistant Top2, which has no current effective drugs in the market for patients.

Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) recently noted in an interview with Investorideas.com “Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in.”

Sunshine Biopharma reported on July 11, 2011 that Adva-27a had shown 16-fold more effectiveness against MCF-7/MDR Multidrug Resistant Breast Cancer and announced on June 26th results that Adva-27a is significantly more effective at killing Multidrug Resistant Small-Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer.

Adva-27a was designed and synthesized de novo in 2006. Patents covering Adva-27a and derivatives have recently issued in the United States and Europe and are pending in other countries around the world. Sunshine Biopharma has announced collaborations with the State University of New York at Binghamton and McGill University’s Jewish General Hospital in Montreal (Canada) focused on the development of Adva-27a through clinical trials.

Herceptin® was developed originally by Genentech, starting with research that dated back to the 1970’s and Roche later signed a licensing agreement in 1998 for exclusive marketing rights for Herceptin outside of the United States. A few months later Herceptin received FDA approval for use in women with breast cancer that overexpresses the HER2 protein. Herceptin® was the first therapeutic antibody targeted to a specific (HER2) cancer-related molecular marker to receive FDA approval. Roche purchased Genentech in March 2009 for approximately $46.8 billion.

The most recent development on Herceptin® was June this year when Roche announced the FDA had approved Perjeta® (pertuzumab) in combination with Herceptin® and docetaxel chemotherapy for the treatment of people with Her2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Herceptin® sales were over $5 billion in 2010 but Herceptin® begins to lose patent protection in world markets in 2014.



About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com

About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for the free investor news and biotech stock alerts

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Junior Biotech Roche (OTCBB: RHHBY) to Start Human Trials in Quest for New Breast Cancer Treatments

Atlanata, GA 5/10/12 (StreetBeat) – The battle against breast cancer looks to be getting a few more weapons in its arsenal in the future. Swiss drug giant Roche took a shot in the arm in November of 2011 when the Food and Drug Administration revoked their Genentech unit’s Avastin as an indication for breast cancer, but Roche (OTCBB: RHHBY) is providing some promising research with their new pertuzumab drug in recent months. The experimental antibody is being used as an addition to Roche’s blockbuster breast cancer drug, Herceptin, and chemotherapy. The latest data shows that the new concoction can add six months to the lives of HER2-positive breast cancer patients. Herceptin, also known as tratuzumab, had 2010 global sales of $6.8 billion.

On the same front, other drug makers are providing optimistic results across the full range of research. Novartis's (NYSE:NVS) is developing Afinitor (everolimus) - which is already approved for other cancers - showed that treatment with it delays disease progression by four months among metastatic patients. Earlier on in development, Sunshine Biopharma(OTCBB:SBFM) is wrapping-up laboratories studies on Adva-27, a small molecule that targets and inhibits Top2, the second enzyme (HER-2 is the other) associated with aggressive forms of breast cancer. Also taking a step in the right direction helping to re-shape the treatments for breast cancer patients is Seattle, Washington-based TapImmune Inc. (OTCBB:TPIV).

A vaccine technology company, TapImmune received allowance from the FDA last year and recently got Institutional Review Board approval for a Phase I clinical trial to be hosted at the Mayo Clinic in Rochester, Minnesota. Today, TapImmune told investors that the company-sponsored trial is set to begin to test its novel set of HER2/neu Class II antigens in breast cancer patients who finished standard Herceptin-based therapy and are at a high risk of disease recurrence.

As a result of what the company called an “overwhelming response” from patients expressing interest to be in the trial, TapImmune expects the trial to be fully subscribed. The primary endpoints of the study will be safety and immunogenicity - the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Representing a significant milestone, this is the first clinical trial to be run to test TapImmune’s HER-2/neu vaccine program.

There are four companies with four different root targets for the treatment of breast cancer with each striving to generate revenue while providing a solution to a disease that took the life of approximately 40,000 women in 2011, with about 300,000 new cases diagnosed. Proper due diligence on each is, as always, encouraged.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly